Healthcare -
Biotechnology - NASDAQ - US
$ 9.05
3.08 %
$ 14.3 M
Market Cap
0.21
P/E
1. INTRINSIC VALUE
2. FUNDAMENTAL
ANALYSIS
Price Chart CYCC
FINANCIALS
Balance Sheet
Cyclacel Pharmaceuticals, Inc.
| Current Assets | 3.67 M |
| Cash & Short-Term Investments | 3.14 M |
| Receivables | 237 K |
| Other Current Assets | 300 K |
| Non-Current Assets | 419 K |
| Long-Term Investments | 0 |
| PP&E | 8 K |
| Other Non-Current Assets | 411 K |
| Current Liabilities | 6.27 M |
| Accounts Payable | 4.6 M |
| Short-Term Debt | 0 |
| Other Current Liabilities | 1.67 M |
| Non-Current Liabilities | 0 |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Cyclacel Pharmaceuticals, Inc.
| Revenue | 43 K |
| Cost Of Revenue | 6 K |
| Gross Profit | 37 K |
| Operating Expenses | 12 M |
| Operating Income | -12 M |
| Other Expenses | -792 K |
| Net Income | -11.2 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Cyclacel Pharmaceuticals, Inc.
| Net Income | -11.2 M |
| Depreciation & Amortization | 6 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 592 K |
| Change in Working Capital | 2.62 M |
| Others | 4.47 M |
| Free Cash Flow | -7.99 M |
Wall Street Analysts Price Targets
Cyclacel Pharmaceuticals, Inc.
Wall Street analysts predict an average 1-year price target for CYCC of $1 , with forecasts ranging from
a
low of
$1 to a high of $1 .
CYCC Lowest Price Target
Wall Street Target
1 USD
-88.95%
CYCC Average Price Target
Wall Street Target
1 USD
-88.95%
CYCC Highest Price Target
Wall Street Target
1 USD
-88.95%
4. DIVIDEND
ANALYSIS
0.00%
DIVIDEND YIELD
0.15 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Cyclacel Pharmaceuticals, Inc.
Sold
0-3 MONTHS
83.4 K USD 1
3-6 MONTHS
5.51 M USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB
- Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis - KUALA LUMPUR, Malaysia, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, highlighted a preclinical study from independent investigators titled, “ Evaluation of antitumor effects of plogosertib, PLK1 inhibitor in biliary tract cancer with BUBR1 as a potential biomarker ” in the journal, Cancer Research, previously reported in a poster at the American Association of Cancer Research 2025 annual meeting.1 The investigators found that several BTC cancer cell lines were sensitive to plogosertib both as monotherapy and in combinations. Consistently with its antimitotic mechanism of action, plogosertib promoted mitotic checkpoint complex (MCC) formation in prometaphase, which induced mitotic arrest resulting in apoptosis of BTC cells.
globenewswire.com
- 1 week ago
Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday?
Cyclacel Pharmaceuticals, Inc. CYCC stock is trading higher on Tuesday, with a session volume of 21.9 million compared to the average volume of 206.9K, as per data from Benzinga Pro.
benzinga.com
- 3 weeks ago
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER
- Fibrolamellar hepatocellular carcinoma (FLC) has no approved treatment and occurs mostly in adolescents and young adults -
globenewswire.com
- 1 month ago
CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT
Kuala Lumpur, Malaysia, July 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced that it has entered into an amendment to the Exchange Agreement with FITTERS Diversified Berhad (9318.KL; “FITTERS”), an investment holding company engaged, through its subsidiaries, in the business of the sale of fire safety materials, equipment and fire prevention systems, “Waste-To-Resource” services and real estate development and construction.
globenewswire.com
- 1 month ago
Cyclacel Pharmaceuticals Announces Stock Split
BERKELEY HEIGHTS, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced that it expects to implement a 1-for-15 reverse stock split on its shares of common stock effective July 7, 2025, with trading to begin on a split-adjusted basis at the market open on that day.
globenewswire.com
- 1 month ago
Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock
KUALA LUMPUR, June 20, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (“Cyclacel”) (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicine, today announced that it has entered into a securities purchase agreement for the sale of its convertible Series F Preferred Stock (“Preferred Stock”) in a private placement to certain accredited investors yielding gross proceeds of $3.0 million before deducting offering expenses. In connection with the offering, Cyclacel issued to each investor, a series A common stock purchase warrant to purchase 3,270,000 shares of the Company's common stock, par value $0.001 per share (“Common Stock”) at an exercise price of $0.51 per share, series B common stock purchase warrant to purchase 3,270,000 shares of Common Stock at an exercise price of $0.60 per share and series C common stock purchase warrant to purchase 3,270,000 shares of Common Stock at an exercise price of $0.68 per share (collectively, the “Warrants”).
globenewswire.com
- 1 month ago
CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
KUALA LUMPUR, MALAYSIA, June 03, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company that develops innovative cancer medicine, today announced that it has received a letter (the “Compliance Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market Inc. (“Nasdaq”) dated June 3, 2025, informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).
globenewswire.com
- 2 months ago
CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
KUALA LUMPUR, MALAYSIA, May 15, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines, today announced its first quarter financial results and provided a business update.
globenewswire.com
- 2 months ago
CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT
BERKELEY HEIGHTS, NJ, May 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced that it expects to implement a 1-for-16 reverse stock split on its shares of common stock effective May 12, 2025, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the shares of common stock will continue on The Nasdaq Capital Market under the symbol “CYCC”. The new CUSIP number for the shares of common stock following the reverse stock split is 23254L884.
globenewswire.com
- 3 months ago
CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN.
KUALA LUMPUR, MALAYSIA, May 06, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”) today announced that it entered into an Exchange Agreement with FITTERS Diversified Berhad (9318.KL; “FITTERS”), an investment holding company engaged, through its subsidiaries, in the business of the sale of fire safety materials, equipment and fire prevention systems, “Waste-To-Resource” services and real estate development and construction.
globenewswire.com
- 3 months ago
Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update
BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced fourth quarter financial results and provided a business update.
globenewswire.com
- 4 months ago
Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock
KUALA LUMPUR, Malaysia, March 24, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicine, today announced that it has entered into a securities purchase agreement for the sale of its convertible Series E Preferred Stock (“Preferred Stock”) in a private placement to certain accredited investors yielding gross proceeds of $1.0 million before deducting offering expenses. The offering closed on March 21, 2025.
globenewswire.com
- 4 months ago
8. Profile
Summary
Cyclacel Pharmaceuticals, Inc. CYCC
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 14.3 M
Dividend Yield
0.00%
Description
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
Contact
200 Connell Drive, Berkeley Heights, NJ, 07922
https://www.cyclacel.com
IPO
Date
March 16, 2004
Employees
12
Officers
Grace Kim
Investor Relations Executive
Mr. Cu Seng Kiu
Executive Director, Chief Financial Officer & Secretary
Ms. Gill Christie
Director of Human Resources
Dr. Sing Ee Wong
Chairman, Chief Executive Officer & President